Edition:
United States

Immune Pharmaceuticals Inc (IMNP.PH)

IMNP.PH on Philadelphia Stock Exchange

2.43USD
20 Jul 2017
Change (% chg)

-- (--)
Prev Close
$2.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,893
52-wk High
$9.74
52-wk Low
$2.21

IMNP.PH

Chart for IMNP.PH

About

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its... (more)
No analyst recommendations are available for IMNP.PH.

Overall

Beta: 2.04
Market Cap(Mil.): $24.81
Shares Outstanding(Mil.): 10.09
Dividend: --
Yield (%): --

Financials

  IMNP.PH Industry Sector
P/E (TTM): -- 11.87 15.95
EPS (TTM): -7.76 -- --
ROI: -170.90 -9.97 -8.24
ROE: -935.94 -9.81 -7.87

BRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia

* Immune Pharmaceuticals provides update on plan to implement a spin-off of Cytovia into a separate publicly traded oncology company

Jul 19 2017

BRIEF-Immune Pharma announces filing of patent protecting use of ceplene

* Immune Pharmaceuticals announces filing of a patent protecting use of ceplene (histamine dihydrochloride) in hematologic cancers

Jul 13 2017

BRIEF-Cytovia Inc enters agreement with Pint Pharma for licensing of Ceplene in Latin America

* Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America

Jul 11 2017

BRIEF-Immune Pharmaceuticals' oncology unit announces additional clinical trial results on the efficacy of Ceplene in combination with low-dose IL-2 in patients with acute myeloid leukemia

* Immune Pharmaceuticals' oncology subsidiary, Cytovia, announces additional clinical trial results on the efficacy of Ceplene® in combination with low-dose IL-2 in patients with acute myeloid leukemia, recently published in leukemia, a leading Hematology Journal

Jul 05 2017

BRIEF-Immune Pharmaceuticals files for offering of upto 1.4 mln shares

* Immune Pharmaceuticals Inc files for offering of upto 1.4 million shares of common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2t04Ovb) Further company coverage:

Jun 30 2017

BRIEF-Immune Pharmaceuticals' Oncology subsidiary, Cytovia Inc. Provides update to proposed pint pharma transaction

* Immune pharmaceuticals' oncology subsidiary, cytovia inc. Provides update to proposed pint pharma transaction: substantial agreement reached on material terms of the licensing and commercialization of ceplene® in latin america

Jun 29 2017

BRIEF-Immune Pharma announces initiation of enrollment in clinical trial with Ceplene

* Immune pharmaceuticals announces initiation of enrollment in clinical trial with ceplene®/ low-dose il-2 in chronic myelomonocytic leukemia (cmml)

Jun 20 2017

BRIEF-Immune receives NASDAQ compliance letter

* Immune receives nasdaq compliance letter Source text for Eikon: Further company coverage:

Jun 19 2017

BRIEF-Immune Pharmaceuticals signs agreement to regain worldwide rights for Ceplene

* Immune Pharmaceuticals signs agreement to regain worldwide rights for Ceplene

Jun 15 2017

BRIEF-Immune Pharmaceuticals files for non-timely 10-Q

* Immune Pharmaceuticals says time required to prepare 2016 10-K resulted in delay in filing of form 10-Q for fiscal quarter ended March 31, 2017 Further company coverage:

May 16 2017

Competitors

Earnings vs. Estimates